Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.07 +1.13%

+$0.05 today

Market cap
$623.90M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.44M

Average 1.76M

Income Statement

Follow revenue through to earnings.

Revenue

$14.08M

FY 2025 · Annual

+128.2% YoY

Operating Income

-$27.05M

FY 2025 · Annual

Net Income

-$33.50M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.99M39.02M18.14M6.17M14.08M
Cost of Revenue0000363K
Gross Profit10.99M39.02M18.14M6.17M13.72M
Gross Margin100.0%100.0%100.0%100.0%97.4%
Research & Development65.5M84.41M73.7M54.04M25.24M
Selling, General & Admin17.14M17.83M22.48M22.11M15.89M
Operating Expenses84.51M104.48M96.24M82.49M40.77M
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
EBITDA(71.64M)(61.86M)(70.99M)(68.4M)(33.04M)
EBITDA Margin-652.0%-158.5%-391.3%-1108.5%-234.6%
Operating Income(73.52M)(65.46M)(78.1M)(76.32M)(27.05M)
Operating Margin-669.1%-167.8%-430.5%-1236.7%-192.1%
Interest Income127K2.19M5.69M6.59M4.07M
Interest Expense2.86M1.73M459K137K97K
Other Income / Expenses(2.73M)444K5.25M6.4M(6.45M)
Income Before Tax(76.25M)(65.01M)(72.85M)(69.92M)(33.5M)
Pre-Tax Margin-693.9%-166.6%-401.6%-1133.0%-237.9%
Income Tax Expense04.44M000
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Net Margin-693.9%-178.0%-401.6%-1133.0%-237.9%
EPS (Basic)(0.73)(0.46)(0.44)(0.38)(0.17)
EPS (Diluted)(0.73)(0.46)(0.44)(0.38)(0.17)
Weighted Avg Shares106.24M150.94M165.96M185.61M191.6M
Weighted Avg Shares (Diluted)106.24M150.94M165.96M185.61M191.6M

ABUS Earnings Waterfall · TTM

NASDAQ:ABUS · Revenue to Net Income

Key Ratios

EPS$0.82
Gross Margin99.2%
Net Margin-425.7%
P/E Ratio-7.4
P/S Ratio645.7

Analysis

$191.4M of revenue converted into $160.7M of net income for the selected period. Gross margin is 99.2% and net margin is -425.7%, showing how much revenue survives after costs and taxes. EPS is $0.82, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
8-KCurrent reportOct 22, 2026

How much revenue does ABUS generate?

Arbutus Biopharma Corporation (ABUS) reported $14.08M of revenue in fiscal 2025.

Is ABUS profitable?

Arbutus Biopharma Corporation (ABUS) reported -$33.50M of net income, with a net margin of -237.9%.